BACKGROUND: A post marketing surveillance study was conducted to evaluate safety and efficacy of natalizumab in Swedish multiple sclerosis (MS) patients since its introduction in August 2006 until March 2010. METHODS: Patients were registered in the web-based Swedish MS-registry at 40 locations and evaluated every 6 months. Adverse events and clinical outcomes were recorded. RESULTS: One thousand one hundred and fifty-two patients were included (71.4% female) and 149 patients stopped treatment; the main reason was planned pregnancy. Anti-natalizumab antibodies were found in 4.5% (52 patients) of which 1.6% displayed persistent antibodies. Serious adverse events were rare, but included three cases with progressive multifocal leukoencephalopathy (PML). There were seven fatal cases, probably unrelated to the natalizumab treatment. For relapsing-remitting MS patients (n=901), mean Expanded Disability Status Scale (EDSS, -10.7%), Multiple Sclerosis Severity Scale (MSSS, -20.4%), Multiple Sclerosis Impact Scale (MSIS-29, physical -9.9%, psychological -13.3%) and Symbol Digit Modalities Test (SDMT, +10.7%) all showed significant improvements during 24 months of treatment with natalizumab. The Swedish web-based MS quality registry proved to function as a platform for post-marketing MS drug surveillance, providing long-term data regarding drug effects and adverse events beyond clinical trials. CONCLUSIONS: Our results indicate that natalizumab is generally well tolerated and has sustained efficacy for patients with active MS, though the risk of PML is still an important concern.
BACKGROUND: A post marketing surveillance study was conducted to evaluate safety and efficacy of natalizumab in Swedish multiple sclerosis (MS) patients since its introduction in August 2006 until March 2010. METHODS:Patients were registered in the web-based Swedish MS-registry at 40 locations and evaluated every 6 months. Adverse events and clinical outcomes were recorded. RESULTS: One thousand one hundred and fifty-two patients were included (71.4% female) and 149 patients stopped treatment; the main reason was planned pregnancy. Anti-natalizumab antibodies were found in 4.5% (52 patients) of which 1.6% displayed persistent antibodies. Serious adverse events were rare, but included three cases with progressive multifocal leukoencephalopathy (PML). There were seven fatal cases, probably unrelated to the natalizumab treatment. For relapsing-remitting MS patients (n=901), mean Expanded Disability Status Scale (EDSS, -10.7%), Multiple Sclerosis Severity Scale (MSSS, -20.4%), Multiple Sclerosis Impact Scale (MSIS-29, physical -9.9%, psychological -13.3%) and Symbol Digit Modalities Test (SDMT, +10.7%) all showed significant improvements during 24 months of treatment with natalizumab. The Swedish web-based MS quality registry proved to function as a platform for post-marketing MS drug surveillance, providing long-term data regarding drug effects and adverse events beyond clinical trials. CONCLUSIONS: Our results indicate that natalizumab is generally well tolerated and has sustained efficacy for patients with active MS, though the risk of PML is still an important concern.
Authors: A Melin; O Outteryck; N Collongues; H Zéphir; M C Fleury; F Blanc; A Lacour; J C Ongagna; A S Berteloot; P Vermersch; J de Sèze Journal: J Neurol Date: 2011-12-13 Impact factor: 4.849
Authors: Jeffrey Wilken; Robert L Kane; Cynthia L Sullivan; Mark Gudesblatt; Sylvia Lucas; Robert Fallis; Xiaojun You; Pam Foulds Journal: Int J MS Care Date: 2013
Authors: Ilya Kister; Eric Chamot; Amber R Salter; Gary R Cutter; Tamar E Bacon; Joseph Herbert Journal: Neurology Date: 2013-02-20 Impact factor: 9.910
Authors: Kathrin S Utz; De-Hyung Lee; Alexandra Lämmer; Anne Waschbisch; Ralf A Linker; Thomas Schenk Journal: Ther Adv Neurol Disord Date: 2016-04-18 Impact factor: 6.570
Authors: Ludwig Kappos; Paul W O'Connor; Christopher H Polman; Patrick Vermersch; Heinz Wiendl; Amy Pace; Annie Zhang; Christophe Hotermans Journal: J Neurol Date: 2013-01-05 Impact factor: 4.849
Authors: D W Langdon; M P Amato; J Boringa; B Brochet; F Foley; S Fredrikson; P Hämäläinen; H-P Hartung; L Krupp; I K Penner; A T Reder; R H B Benedict Journal: Mult Scler Date: 2011-12-21 Impact factor: 6.312